1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Poster Session

Start Session

Thumbnail for Two-Year Rituximab Maintenance vs Observation After First-Line Treatment With Bendamustine Plus Rituximab (B-R) in Patients With Waldenström’s Macroglobulinemia: Results of a Prospective, Randomized Multicenter Phase 3 Study (StiL NHL7-2008 MAINTAIN Trial

IBCL - 549

Two-Year Rituximab Maintenance vs Observation After First-Line Treatment With Bendamustine Plus Rituximab (B-R) in Patients With Waldenström’s Macroglobulinemia: Results of a Prospective, Randomized Multicenter Phase 3 Study (StiL NHL7-2008 MAINTAIN Trial

Mathias Rummel

Poster Presenter: Mathias Rummel

Thumbnail for Administering Tafasitamab, Lenalidomide and Rituximab for Follicular Lymphoma: a Single Institution Experience From the Phase 3 inMIND Study

IBCL - 552

Administering Tafasitamab, Lenalidomide and Rituximab for Follicular Lymphoma: a Single Institution Experience From the Phase 3 inMIND Study

Danielle Janiszewski

Poster Presenter: Danielle Janiszewski

Video

Thumbnail for Racial Disparities in Incidence of Non-Hodgkin Lymphoma as a Second Primary Malignancy Following Prostate Cancer: A Population-Based Study

IBCL - 665

Racial Disparities in Incidence of Non-Hodgkin Lymphoma as a Second Primary Malignancy Following Prostate Cancer: A Population-Based Study

Damilola Ologbe

Poster Presenter: Damilola Ologbe

IBCL - 683

Histologic Transformation Drives the Adverse Prognosis of POD24 in a Cohort of Patients With Follicular Lymphoma in Mexico

Laura Elena Valdovinos-Elizalde

Poster Presenter: Laura Elena Valdovinos-Elizalde

$Thumbnail for Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND$

IBCL - 740

Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND

Moshe Levy

Poster Presenter: Moshe Levy

Thumbnail for Retrospective Analysis of Cardiovascular Risk Assessment Prior to BTK Inhibitor Treatment for Patients with CLL and B-cell Lymphomas

IBCL - 907

Retrospective Analysis of Cardiovascular Risk Assessment Prior to BTK Inhibitor Treatment for Patients with CLL and B-cell Lymphomas

Nicholas Demetriou

Poster Presenter: Nicholas Demetriou

IBCL - 936

Chronification of Follicular Lymphoma Mortality: A 22-Year National Multiple-Cause-of-Death Analysis, 2003-2024

Kristina Agustino

Poster Presenter: Kristina Agustino

$Thumbnail for Efficacy of Vemurafenib in Relapsed/Refractory Hairy Cell Leukemia: A Systematic Review and Meta Analysis$

IBCL - 960

Efficacy of Vemurafenib in Relapsed/Refractory Hairy Cell Leukemia: A Systematic Review and Meta Analysis

Sandeep Guntuku

Poster Presenter: Sandeep Guntuku

MCL - 1013

Concurrent High-Risk Features in Mantle Cell Lymphoma: Frequency and Impact

Carla Isabel Borre

Poster Presenter: Carla Isabel Borre